PriceTracker GLP-1
Loading the index…

Try

Find the cheapest for me
Loading the index…

Try

GLP-1 TV · News & media

Orforglipron Phase 3 Data: Dr. Michael Weintraub Reviews ATTAIN-1 and ACHIEVE-1 Findings

News & media9:57Aug 2025

Today’s cheapest GLP-1$39/mo at Wellmedr, sale price.Compare all GLP-1 prices Price read 22 Nov 2026 from the seller’s own page, ranked by price alone. That price is a compounded drug, and compounded drugs are not FDA-approved. Not from the video’s creator.

Our summary

The speaker reviews phase 3 results for orforglipron, an oral small molecule GLP-1 medication. He says the ATTAIN-1 trial showed 12.4% weight loss over 72 weeks in people with obesity without diabetes, and the ACHIEVE trial in type 2 diabetes showed 7.6% weight loss. He compares this with tirzepatide and semaglutide, which he says produce 15 to 20% and 10 to 15% weight loss respectively, so he describes orforglipron as falling short of those weekly injectables. Against other oral small molecules, he calls it the greatest weight loss seen to date, and he names Qsymia as the only real comparator.

Published by Metabolic Care Today on YouTube

As published by the channel. Not medical advice, and not an endorsement.

What else the video covers

He says he would offer an oral option mainly to people who are unwilling or unable to use injectables. On health markers, ATTAIN-1 topline data reported a 47% improvement in CRP, while the full ACHIEVE manuscript showed better lipid profiles and a 1.6% A1C improvement. He cautions that a small molecule may not deliver the same cardiovascular risk reduction seen with the peptide drugs until outcomes data exist.

On convenience, he says many patients would pick a daily pill over a weekly shot, but some prefer a weekly injection for adherence reasons. In ATTAIN-1 he reports 33% nausea, 24% vomiting and a 10.3% discontinuation rate due to adverse events, which looked higher at first glance but closer to other GLP-1 drugs in the ACHIEVE data. He hopes a non-peptide pill will lower prices and improve insurance coverage in the United States, where he calls access poor.

Our summary of what is said, in our words. Doses, results and prices are the speaker’s, not advice.

Takeaways

The main points, in the order they come up. Tap a time to play from there.

  1. 0:16 The speaker says tirzepatide and semaglutide set the efficacy bar at 15 to 20% and 10 to 15% weight loss, respectively.
  2. 0:46 He reports ATTAIN-1 weight loss of 12.4% over 72 weeks without diabetes, which he says falls short of the injectables but is the best yet for an oral small molecule.
  3. 2:20 He would offer orforglipron mainly to people who are unwilling or unable to take injectables.
  4. 2:50 He cites a 47% CRP improvement in ATTAIN-1 topline results and a 1.6% A1C improvement in ACHIEVE, but says cardiovascular benefit is not yet proven for a small molecule.
  5. 6:28 He reports 33% nausea, 24% vomiting and a 10.3% discontinuation rate in ATTAIN-1, and judges side effects comparable to weekly injectables overall.
  6. 8:35 He hopes an oral small molecule will lower costs and improve insurance coverage.

Key moments

Tap one to play from there.

  1. 1:17 The trials
  2. 2:17 Weigh-in and results
  3. 5:20 Injection technique
  4. 6:33 Side effects
  5. 8:43 Cost and insurance

What the video says

As stated in the video, not checked by us. Doses and results are the speaker’s, not advice.

Medication
Foundayo
Side effects mentioned
nausea and vomiting

Questions this video answers

How much weight did people lose on orforglipron in the ATTAIN-1 trial?

According to the speaker, ATTAIN-1 showed 12.4% weight loss over 72 weeks in people with obesity without diabetes. The ACHIEVE trial in type 2 diabetes showed 7.6% weight loss.

How does orforglipron compare with tirzepatide and semaglutide?

The speaker says tirzepatide and semaglutide produce 15 to 20% and 10 to 15% weight loss respectively, so orforglipron falls short of them. He adds that it is the greatest weight loss seen so far with an oral small molecule medication.

What side effects did orforglipron have in ATTAIN-1?

The video reports 33% nausea and 24% vomiting, with 10.3% of participants stopping due to adverse events. The speaker says the ACHIEVE discontinuation data looked closer to other GLP-1 drugs and the overall side effect profile is comparable to weekly injectables.

Who might orforglipron be for?

The speaker says he would offer an oral medication to people who are unwilling or unable to take injectables. He also notes that patient preference between a daily pill and weekly shot varies.

Videos on the same question

The closest videos in the library by what is said in them, not by title.

Read next

Our guides closest to what this video covers, with prices checked weekly.

  • Mounjaro vs Ozempic, and the trial everyone quotes about it

    Mounjaro is tirzepatide and Ozempic is semaglutide: different molecules, not two brands of the same drug. Both are approved for type 2 diabetes, and the weight-loss versions are Zepbound and Wegovy. In the one head-to-head trial, SURMOUNT-5, tirzepatide produced 20.2% mean body-weight loss at 72 weeks against semaglutide's 13.7%. The detail almost every page omits: that trial dosed semaglutide to 2.4 mg in people without diabetes, which is the Wegovy range. Ozempic tops out at 2 mg. The famous result did not test Ozempic's dose range.

  • The best GLP-1 for weight loss, ranked by the evidence and then by the bill

    By weight lost, the order is settled: tirzepatide (Zepbound) first at 20.2% in the only head-to-head, then semaglutide 7.2 mg (Wegovy HD) at 18.7%, then semaglutide 2.4 mg (Wegovy) at 13.7% to 15.6%, then the pills. By what you pay, the order nearly inverts: compounded semaglutide from $39 a month, the Wegovy tablet from $149, Wegovy pen $349, Zepbound $299 to $699 by dose. The best one is where those two lists meet for your budget and your plan.

  • Semaglutide for weight loss: which version, and what each costs

    Semaglutide is the molecule. For weight loss the FDA-approved version is Wegovy, sold as a weekly pen and a daily tablet. Ozempic is the same molecule approved for type 2 diabetes, so using it for weight is off-label. Compounded semaglutide uses semaglutide as its active ingredient, comes from a compounding pharmacy, is not FDA-approved, and is what most cash buyers actually take because it costs a fraction of the brand. All three produce the same side effects. What differs is the approval, the oversight and the price.

Next steps

Foundayo prices

Find more like it

Side effectsDose changeWeigh-in and resultsCost and insuranceHow it worksThe trialsNauseaVomiting

Up next

More from this collection

Watched it? See what it costs.

Every GLP-1 program we track, ranked by what actually leaves your account.

Back to GLP-1 TV